Leading five global anti-viral products by revenue 2017 and 2024

This statistic displays the top 5 global anti-viral products base on their revenue worldwide in 2017, and a projection for 2024. Gilead Sciences' Genvoya is expected to generate 3.4 billion U.S. dollars in revenues by 2024.

Top 5 global anti-viral products based on revenue in 2017 and 2024

20172024*
---
---
---
---
---
Exclusive Premium statistic

You need a Premium Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Premium Account

only $59 / month *
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in
Source

Release date

June 2018

Region

Worldwide

Survey time period

as of May 2018

Supplementary notes

This statistic is ranked by 2024 revenues.
* Projected.

Statista Accounts: Access All Statistics. Starting from $708 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account!

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$59 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.

Statistics on "Top pharmaceutical drugs"

Statista Accounts: Access All Statistics. Starting from $708 / Year
Learn more about how Statista can support your business.